

November 24, 2015
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer

Symbio Partner Announces European Approval of IONSYS®

TOKYO, Japan, November 24, 2015 --- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, “Symbio”), today announced that its U.S. partner, The Medicines Company (Headquarters: Parsippany, NJ, “MDCO”), announced on November 20, 2015 approval of IONSYS® (iontophoretic transdermal system, “IONSYS”) in Europe indicated for the management of acute moderate to severe post-operative pain in adult patients.

IONSYS® received approval from the U.S. Food and Drug Administration on April 30, 2015 and it is already on the market in the U.S.

In October 2015, Symbio and MDCO entered into a strategic partnership for IONSYS® (fentanyl iontophoretic transdermal system) in Japan under which Symbio was granted an exclusive license in Japan to develop and commercialize IONSYS.

Symbio is currently preparing to initiate the phase 3 study in the second half of 2016.

[Contact]

Investor Relations
Tel: +81 (0)3 5472 1125

About Symbio Pharmaceuticals Limited

Symbio Pharmaceuticals Ltd. was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading specialty pharmaceutical company in the Asia Pacific region dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and autoimmune disease.